In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott Diabetes Care Inc.

Division of Abbott Laboratories Inc.

Latest From Abbott Diabetes Care Inc.

Dexcom Stocks Continue To Drop After Short-Seller Warns of Competition From Abbott

Investment managing firm Spruce Point says factors such as patients hacking their older Dexcom continuous glucose meters, the company’s decision to not disclose its patient base and competition from Abbott’s upcoming Libre 2 CGMs are red flags that Dexcom is overstating its market potential. Dexcom's stocks lost a fifth of their value after the short-seller released a recent report that says the firm is overvalued.

Market Access Pricing Strategies

ADA2018: Senseonics' Implantable CGM Beats Abbott, Dexcom In Head-To-Head Study – But Is Methodology Flawed?

In a three-way patient study comparing the accuracy of three currently available continuous glucose monitoring (CGM) devices, the newly FDA-approved Eversense by Senseonics performed significantly better than the Abbott Freestyle Libre Pro and Dexcom G5. The study findings were presented during this year's annual American Diabetes Association meeting in Orlando, Florida. This article also discusses other highlights presented by the three companies at the ADA conference.

Diabetic Care Clinical Trials

Dexcom Gains Approval For No-Calibration, 'Interoperable' CGM System

US FDA's March 27 de novo clearance of the Dexcom G6 integrated continuous glucose monitoring (iCGM) system for diabetics gives Dexcom a no-calibration offering, a first-in-class "interoperable" system and sets out a streamlined regulatory pathway for future CGM devices with similar features.

Diabetic Care In Vitro Diagnostics

Abbott 'No-Fingerstick' CGM System For Diabetes Wins Medicare Coverage

The first continuous glucose monitoring (CGM) system for diabetics that avoids fingerstick calibrations, the Abbott Freestyle Libre, now will be covered through Medicare under therapeutic CGM systems reimbursement codes.

Diabetic Care Medicare
See All

Company Information

  • Industry
  • In Vitro Diagnostics
    • Biosensors
    • Glucose Testing
  • Medical Devices
    • Monitoring Equipment & Devices
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • MediSense Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Abbott Laboratories Inc.
  • Senior Management
  • Christophe Begley, VP, Gen. Mgr.
    Kenneth D Stiles, Controller
    Donald L Pieper, PhD, VP, R&D
    Peter C Gonze, VP, Retail Sales & Mktg.
  • Contact Info
  • Abbott Diabetes Care Inc.
    Phone: (510) 749-5400
    1360 South Loop Rd.
    Alameda, CA 94502